RT Journal Article SR Electronic T1 SARS-CoV-2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.03.21252838 DO 10.1101/2021.03.03.21252838 A1 Gage K. Moreno A1 Katarina M. Braun A1 Ian W. Pray A1 Hannah E. Segaloff A1 Ailam Lim A1 Keith Poulson A1 Jonathan Meiman A1 James Borcher A1 Ryan P. Westergaard A1 Michael K. Moll A1 Thomas C. Friedrich A1 David H. O’Connor YR 2021 UL http://medrxiv.org/content/early/2021/03/06/2021.03.03.21252838.abstract AB Background High frequency, rapid turnaround SARS-CoV-2 testing continues to be proposed as a way of efficiently identifying and mitigating transmission in congregate settings. However, two SARS-CoV-2 outbreaks occurred among intercollegiate university athletic programs during the fall 2020 semester despite mandatory directly observed daily antigen testing.Methods During the fall 2020 semester, athletes and staff in both programs were tested daily using Quidel’s Sofia SARS Antigen Fluorescent Immunoassay (FIA), with positive antigen results requiring confirmatory testing with real-time reverse transcription polymerase chain reaction (RT-PCR). We used genomic sequencing to investigate transmission dynamics in these two outbreaks.Results In Outbreak 1, 32 confirmed cases occurred within a university athletics program after the index patient attended a meeting while infectious despite a negative antigen test on the day of the meeting. Among isolates sequenced from Outbreak 1, 24 (92%) of 26 were closely related, suggesting sustained transmission following an initial introduction event. In Outbreak 2, 12 confirmed cases occurred among athletes from two university programs that faced each other in an athletic competition despite receiving negative antigen test results on the day of the competition. Sequences from both teams were closely related and unique from strains circulating in the community, suggesting transmission during intercollegiate competition.Conclusions These findings suggest that antigen testing alone, even when mandated and directly observed, may not be sufficient as an intervention to prevent SARS-CoV-2 outbreaks in congregate settings, and highlights the importance of supplementing serial antigen testing with appropriate mitigation strategies to prevent SARS-CoV-2 outbreak in congregate settings.Summary High frequency, rapid turnaround SARS-CoV-2 testing continues to be proposed as a way of efficiently identifying and mitigating transmission in congregate settings. However, here we describe two SARS-CoV-2 outbreaks occurred among intercollegiate university athletic programs during the fall 2020 semester.Competing Interest StatementThe findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention. Funding StatementThis work was supported by COVID-19 Response grant from the Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health to TCF and DHO. GKM is supported by an NLM training grant to the Computation and Informatics in Biology and Medicine Training Program (NLM 5T15LM007359).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained a waiver of HIPAA Authorization and were approved to obtain the clinical samples along with a Limited Data Set by the Western Institutional Review Board (WIRB #1-1290953-1). The names of universities, the specific sports, and relevant dates have been removed from the report to protect the privacy of the students and staff involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data after mapping to SARS-CoV-2 reference genome (Genbank: MN908947.3) have been deposited in the Sequence Read Archive (SRA) under bioproject PRJNA614504. https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA614504